SLU-PP-332 research: studies, doses and safety
An exercise-mimicking research chemical with mouse benefits and no human dosing trials.
Also called: SLU PP 332, SLUPP332, SLUPP-332.
Exercise mimetics · Pan-estrogen-related receptor (ERRα/β/γ) agonist · Evidence: Animal studies only.
No human dosing study found. Ten relevant records cover animal experiments, human-derived cells, laboratory metabolism, chemical design and a preclinical review.
Key studies
- Mouse endurance: ERR activation increased treadmill endurance in mice. (source)
- Mouse obesity and metabolism: The compound reduced fat gain in mouse obesity models. (source)
- Mouse heart failure: ERR agonists improved some heart outcomes in a mouse disease model. (source)
- Aging mouse kidneys: Kidney aging markers improved in mice. (source)
- Human muscle cells in a dish: Human-derived cells responded in the lab; no one was dosed. (source)
- Oral absorption comparison: An orally active successor does not validate oral SLU-PP-332. (source)
Related to SLU-PP-332
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- SS-31 (elamipretide): A peptide approved for Barth syndrome muscle strength; benefit needs confirmation and broader energy benefits remain unproven.
- 5-amino-1MQ: An experimental NNMT blocker with animal findings, no human dosing trials and uncertain risks.
Sources
- 2027 Prohibited List: Summary of Changes, UK Anti-Doping · 2026
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Low blood sugar (hypoglycaemia), NHS · 2023
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.